Company intelligence / Profile preview

Phoenix Life Sciences

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Phoenix Life Sciences delivers plant-based pharmaceutical products and healthcare management services with a primary focus on diabetes management and expanding indications in pain, cancer, autoimmunity, anxiety, and related diseases, primarily deployed at the clinic and community care level in developing and emerging markets. The company's flagship program, PHOENIX METABOLIC, targets type 2 diabetes management and complications, and programs are active and expanding in the Western Pacific with global ambitions.[2]

Therapeutic areas: ImmunologyEndocrinologyNeurologyPsychiatryOncology
Modalities: Plant based pharmaceuticalSmall molecule
Industry: Biotech

Drug pipeline

2 assets

Phoenix Sleep

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Phoenix Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Life Sciences.

Explore the full profile